ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients

Qu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*苏州大学; 1
Frontiers in Immunology2022-8-17DOI: 10.3389/fimmu.2022.969660
8被引17阅读
引用收藏
分享

摘要

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin's lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, respectively. The median progression-free survival (PFS) was 10.2 months and overall survival (OS) was undefined. The 2-year OS and PFS rates were 54.3% and 47.2%, respectively. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CAR-T-related mortality. Further subgroup analysis showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2-year OS and PFS for patients who achieved CR within 3 months (undefined versus undefined P=0.021 and undefined versus undefined P=0.036) or during the follow-up period were significantly longer than those who did not (undefined versus 4.6 months P < 0.0001 and undefined versus 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-year OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 months versus undefined PP=0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients.

学科与关键词

关键词
chimeric antigen receptor T cellsrelapsedrefractorydiffuse large B-cell lymphomadecitabinecomplete remission
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-08-17
卷期
第 13 卷
页码
969660
DOI
10.3389/fimmu.2022.969660
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Key R&D Program of China [2016YFC0902800]; Priority Academic ProgramDevelopment of Jiangsu Higher Education Institutions (PAPD); National Natural Science Foundation of China [81400155, 81600114]; Jiangsu Natural Science Foundation of China [BK20140374]; Top-notch young health talents, 5th Suzhou health professionals program [GSWS2019035]; National Clinical Research Center for hematologic disease [2021ZKMC01, 2021ZKMB03]

作者

  • Q

    Qu, Changju (通讯) (第一作者)

    1 · soochow univ

  • Z

    Zou, Rui

    1 · soochow univ

查看全部 12 位作者收起作者
  • W

    Wang, Peng

    1 · soochow univ

  • Z

    Zhu, Qian

    soochow univ · 1

  • K

    Kang, Liqing

  • P

    Ping, Nana

    1 · soochow univ

  • X

    Xia, Fan

    1 · soochow univ

  • L

    Liu, Hailing

    yangzhou univ

  • K

    Kong, Danqing

    1 · soochow univ

  • Y

    Yu, Lei

  • W

    Wu, Depei (通讯)

    1 · soochow univ

  • J

    Jin, Zhengming (通讯)

    1 · soochow univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417